Causal mechanisms of cancer chemotherapy-induced painful neuropathy

Kings College London

To start: 1st October 2017


1 fully funded 3-year PhD studentship supported by the Pain Relief Foundation and the Wolfson Centre for Age-Related Diseases


Chemotherapy-induced painful neuropathy (CIPN) is the major dose-limiting side-effect of several widely-used, first-line chemotherapeutics impacting survival and quality of life in millions of patients worldwide, every year. There is no treatment to prevent or reverse CIPN. Thus, the emergence of neuropathy causes dose reduction or cessation of effective cancer treatment, limiting patient survival. This studentship aims to facilitate the development of adjunct therapies, enabling current anti-tumour drugs to be more effectively used and better tolerated, thereby improving patient survival and quality of life.

For further information and how to apply please see the following link